AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21030558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo anti-CD3/anti-CD28 costimulated autologous T cells + pneumococcal conjugate vaccine + multipeptide tumor antigen vaccine
Number of subjects: 54
Study 21030558 — intervention group
Group type: COMPARATOR
Intervention: Pneumococcal conjugate vaccine only
Number of subjects: 54
Study 21030579 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper tertile of GFR (GFR>4.13 ml/min per 1.73 m2)
Number of subjects: 552
Study 21030579 — intervention group
Group type: COMPARATOR
Intervention: Anuric patients (urinary output<100 ml/24 h)
Number of subjects: 552
Study 21030700 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg alteplase
Number of subjects: 57
Study 21030717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapericardial fat (IPF)
Number of subjects: 107
Study 21030717 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrapericardial fat (EPF)
Number of subjects: 107
Study 21030717 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium score
Number of subjects: 107
Study 21030717 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow reserve
Number of subjects: 107
Study 21030717 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperemic myocardial blood flow (MBF)
Number of subjects: 107
Study 21034418 — intervention group
Group type: EXPERIMENTAL
Intervention: c-SN6j (chimeric anti-ENG monoclonal antibody)
Number of subjects: 0
Study 21034448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (healthy smokers)
Number of subjects: 0
Study 21034448 — intervention group
Group type: COMPARATOR
Intervention: Healthy nonsmokers
Number of subjects: 0
Study 21034899 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincter ablation
Number of subjects: 0
Study 21034899 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 21035177 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent peanut consumption during pregnancy
Number of subjects: 503
Study 21035177 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent peanut consumption during pregnancy among infants never breast-fed
Number of subjects: 503
Study 21035177 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE levels to milk
Number of subjects: 503
Study 21035177 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE levels to egg
Number of subjects: 503
Study 21035177 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 503
Study 21035177 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwhite race
Number of subjects: 503
Study 21035624 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 100 mg PO
Number of subjects: 12
Study 21035624 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 250 mg PO
Number of subjects: 12
Study 21035955 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg daily with SRS
Number of subjects: 10
Study 21037128 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM-IV criteria
Number of subjects: 563
Study 21037128 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-10 criteria
Number of subjects: 563
Study 21037128 — intervention group
Group type: EXPERIMENTAL
Intervention: MDAS cutoff score of 10
Number of subjects: 563
Study 21037128 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium Index cutoff score of 7
Number of subjects: 563
Study 21037129 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SAA (mean=2.4 [SD=0.9], n=23)
Number of subjects: 30
Study 21037129 — intervention group
Group type: COMPARATOR
Intervention: High SAA (mean=5.1 [SD=2.4], n=7)
Number of subjects: 30
Study 21037129 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (low and high SAA)
Number of subjects: 30
Study 21037195 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 milligrams of zoledronic acid (ZOL) once yearly
Number of subjects: 5903
Study 21037195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5903
Study 21037442 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sphincter augmentation device (LINX Reflux Management System)
Number of subjects: 44
Study 21039676 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon capsule endoscopy (CCE)
Number of subjects: 545
Study 21039676 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy (gold standard)
Number of subjects: 545
Study 21040519 — intervention group
Group type: EXPERIMENTAL
Intervention: VP shunt using the height/weight-based valve pressure-setting scheme
Number of subjects: 100
Study 21041183 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg i.v. every 2 weeks) plus Erlotinib (150 mg/d orally)
Number of subjects: 40
Study 21041183 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker analysis of tumor cell VEGF-A expression
Number of subjects: 40
Study 21041705 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 10 mg/d intravenously for 10 days
Number of subjects: 32
Study 21041705 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab treatment
Number of subjects: 32
Study 21042071 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin treatment for male pattern baldness
Number of subjects: 0
Study 21042103 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green 4 mg per injection
Number of subjects: 6
Study 21042103 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green 6 mg per injection
Number of subjects: 6
Study 21042103 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green 2 mg per injection
Number of subjects: 6
Study 21044339 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex + Olanzapine
Number of subjects: 0
Study 21044339 — intervention group
Group type: COMPARATOR
Intervention: Divalproex + Placebo
Number of subjects: 0
Study 21045179 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma imaging (740-mBq technetium 99m sestamibi injection)
Number of subjects: 1007
Study 21045179 — intervention group
Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 1007
Study 21045179 — intervention group
Group type: EXPERIMENTAL
Intervention: Both gamma imaging and mammography combined
Number of subjects: 1007
Study 21045179 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma imaging
Number of subjects: 1007
Study 21047224 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (3.0 mg/m² orally)
Number of subjects: 28
Study 21047225 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (SGN-35) at a dose of 0.1 to 3.6 mg per kilogram of body weight every 3 weeks
Number of subjects: 45
Study 21047225 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (SGN-35)
Number of subjects: 45
Study 21047927 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie diet, relative physical inactivity, and administration of prednisolone (37.5 mg/d) for 12 days
Number of subjects: 10
Study 21048059 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating with mothers
Number of subjects: 50
Study 21048059 — intervention group
Group type: COMPARATOR
Intervention: Eating with friends
Number of subjects: 50
Study 21048060 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein restriction with medical food (n = 17 of 29)
Number of subjects: 29
Study 21048060 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein restriction with medical food and supplemental isoleucine or valine (n = 5 of 29)
Number of subjects: 29
Study 21048060 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural protein alone for dietary needs (n = 7 of 29)
Number of subjects: 29
Study 21051557 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lenalidomide (50 mg daily for up to 2 cycles)
Number of subjects: 33
Study 21051557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lenalidomide (10 mg daily after HD lenalidomide)
Number of subjects: 33
Study 21051706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.05 mL) treatment
Number of subjects: 30
Study 21054208 — intervention group
Group type: COMPARATOR
Intervention: Ala/Ala group
Number of subjects: 83
Study 21054208 — intervention group
Group type: EXPERIMENTAL
Intervention: Thr/Thr group
Number of subjects: 83
Study 21054208 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH-stimulated TSH and free T4 levels
Number of subjects: 83
Study 21054764 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group (5386 women)
Number of subjects: 8281
Study 21054764 — intervention group
Group type: COMPARATOR
Intervention: Unscreened group (2895 women)
Number of subjects: 8281
Study 21054764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytological AGC diagnosis
Number of subjects: 8281
Study 21054764 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥60 years
Number of subjects: 8281
Study 21054764 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous screening status
Number of subjects: 8281
Study 21055747 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinagolide (25-75 μg/d) administered for 18-20 weeks after L1
Number of subjects: 9
Study 21055747 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinagolide (25-75 μg/d)
Number of subjects: 9
Study 21057003 — intervention group
Group type: COMPARATOR
Intervention: MMP-9 knockout mice
Number of subjects: 0
Study 21057003 — intervention group
Group type: EXPERIMENTAL
Intervention: Human macrophage mRNA isolated from subjects with emphysema
Number of subjects: 0
Study 21057003 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating monocytes in individuals with advanced emphysema severity
Number of subjects: 0
Study 21057794 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety-engineered devices (mechanical aspirating syringe, antineedlestick safety needle)
Number of subjects: 110
Study 21059176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg on demand (1-3 hours before intercourse) for 12 or 24 weeks
Number of subjects: 6081
Study 21059176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg on demand (1-3 hours before intercourse) for 12 or 24 weeks
Number of subjects: 6081
Study 21059176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6081
Study 21059176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg daily (included in safety assessments only) or on demand for 9 weeks
Number of subjects: 6081
Study 21059176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine (both doses)
Number of subjects: 6081
Study 21059672 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg/day s.c.) and MTX
Number of subjects: 32
Study 21059672 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene profiling
Number of subjects: 32
Study 21059672 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1β associated genes
Number of subjects: 32
Study 21060028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib at 12 mg/m(2)/d
Number of subjects: 16
Study 21060028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib at 8 mg/m(2)/d
Number of subjects: 16
Study 21060028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib at 17 mg/m(2)/d
Number of subjects: 16
Study 21060028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib
Number of subjects: 16
Study 21060320 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell manipulation for asthma therapies
Number of subjects: 0
Study 21060320 — intervention group
Group type: COMPARATOR
Intervention: T(H)2 cytokines (IL-4, IL-5, IL-13)
Number of subjects: 0
Study 21062137 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/valsartan 300/320 mg
Number of subjects: 601
Study 21062137 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/valsartan/HCT (12.5 or 25 mg)
Number of subjects: 601
Study 21062137 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/valsartan with or without HCT
Number of subjects: 601
Study 21062428 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon ion boost in conjunction with photon radiotherapy
Number of subjects: 0
Study 21062428 — intervention group
Group type: COMPARATOR
Intervention: Standard photon treatment
Number of subjects: 0
Study 21062463 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking compression 2.4 mm plates for distal radius fractures
Number of subjects: 2
Study 21062463 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal humerus internal locking plates for proximal humerus fractures
Number of subjects: 2
Study 21062463 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 2
Study 21062463 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 2
Study 21069335 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m(2)) and Docetaxel (75 mg/m(2))
Number of subjects: 62
Study 21069335 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed and Docetaxel (escalating doses)
Number of subjects: 62
Study 21070142 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate 6 mg/kg/day for 7 days
Number of subjects: 26
Study 21070142 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate 4 mg/kg/day for 7 days
Number of subjects: 26
Study 21070142 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate 2 mg/kg/day for 7 days
Number of subjects: 26
Study 21070531 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 0
Study 21070978 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counseling via telemedicine
Number of subjects: 74
Study 21071497 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox therapy (mean dose 36.1 ± 7.7 mg/kg/d during the second year)
Number of subjects: 101
Study 21071497 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox therapy
Number of subjects: 101
Study 21071723 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (tissue plasminogen activator [tPA])
Number of subjects: 109
Study 21071723 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized weighing before thrombolysis
Number of subjects: 109
Study 21071966 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialyzer designed for increased internal filtration
Number of subjects: 12
Study 21071966 — intervention group
Group type: COMPARATOR
Intervention: Control dialyzer
Number of subjects: 12
Study 21072184 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavopiridol
Number of subjects: 35
Study 21072603 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training (marathon running)
Number of subjects: 114
Study 21072603 — intervention group
Group type: COMPARATOR
Intervention: Control group (inactive individuals)
Number of subjects: 114
Study 21073392 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (median dose 90 mg/day)
Number of subjects: 21
Study 21074011 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous LNG 90 mcg/EE 20 mcg
Number of subjects: 79
Study 21075272 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate and naltrexone hydrochloride extended release capsules (MS-sNT)
Number of subjects: 465
Study 21078419 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy regimens with anthracyclines or anthracycline/taxane combination
Number of subjects: 0
Study 21078419 — intervention group
Group type: EXPERIMENTAL
Intervention: MFI-20 (Multidimensional Fatigue Inventory)
Number of subjects: 0
Study 21078419 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 (European Organization for Research and Treatment Quality of Life Questionnaire)
Number of subjects: 0
Study 21078419 — intervention group
Group type: EXPERIMENTAL
Intervention: LOR (Life Orientation Test)
Number of subjects: 0
Study 21078419 — intervention group
Group type: EXPERIMENTAL
Intervention: STAI (State-Trait Anxiety Questionnaire)
Number of subjects: 0
Study 21078684 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery (RYGB)
Number of subjects: 119
Study 21078684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 119
Study 21078684 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight subjects with normal glucose tolerance (NGT)
Number of subjects: 119
Study 21079154 — intervention group
Group type: EXPERIMENTAL
Intervention: BEACOPP chemotherapy (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)
Number of subjects: 99
Study 21079154 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation therapy for rapid responders (females: 4 cycles of COPP/ABV without IFRT; males: 2 cycles of ABVD with IFRT)
Number of subjects: 99
Study 21079154 — intervention group
Group type: EXPERIMENTAL
Intervention: BEACOPP chemotherapy with IFRT for slow responders
Number of subjects: 99
Study 21079154 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 99
Study 21079154 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary leukemias
Number of subjects: 99
Study 21079158 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 141
Study 21079158 — intervention group
Group type: COMPARATOR
Intervention: Control (age-matched, no oncological treatment)
Number of subjects: 141
Study 21079979 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal variation and environmental influence (climatic changes and environmental pollution)
Number of subjects: 0
Study 21079979 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of spina bifida
Number of subjects: 0
Study 21080009 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal system
Number of subjects: 54
Study 21083386 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation in HIV-infected patients
Number of subjects: 150
Study 21083543 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab retreatment (80 mg at week 0 and 40 mg eow starting at week 1)
Number of subjects: 285
Study 21083543 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab retreatment
Number of subjects: 285
Study 21083592 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin use
Number of subjects: 1049
Study 21083592 — intervention group
Group type: COMPARATOR
Intervention: Control (non-users of silymarin)
Number of subjects: 1049
Study 21083644 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 0
Study 21083644 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21084397 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS group
Number of subjects: 74
Study 21085552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) consisting of 6 weekly sessions and 3 telephone booster calls.
Number of subjects: 23
Study 21086246 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel® 120 mg at 56-day interval
Number of subjects: 35
Study 21086246 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel® 120 mg at 42-day interval
Number of subjects: 35
Study 21086246 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel® 120 mg at 28-day interval
Number of subjects: 35
Study 21086246 — intervention group
Group type: COMPARATOR
Intervention: Lanreotide Autogel® 120 mg
Number of subjects: 35
Study 21086246 — intervention group
Group type: COMPARATOR
Intervention: Octreotide LAR
Number of subjects: 35
Study 21086905 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 138
Study 21086905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 21087331 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate ICD shocks
Number of subjects: 134
Study 21087331 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate ICD shocks
Number of subjects: 134
Study 21087331 — intervention group
Group type: COMPARATOR
Intervention: Antitachycardia pacing (ATP)
Number of subjects: 134
Study 21087331 — intervention group
Group type: COMPARATOR
Intervention: Nonsustained ventricular tachycardia
Number of subjects: 134
Study 21087756 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 191
Study 21087756 — intervention group
Group type: COMPARATOR
Intervention: Metallic platform stents (MPS)
Number of subjects: 191
Study 21087953 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciliary neurotrophic factor (CNTF) treatment delivered by an encapsulated cell technology implant in one eye
Number of subjects: 3
Study 21087953 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery in the contralateral eye
Number of subjects: 3
Study 21087958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg) or ranibizumab (0.5 mg)
Number of subjects: 62
Study 21088439 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus paclitaxel
Number of subjects: 57
Study 21091740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 69
Study 21091740 — intervention group
Group type: COMPARATOR
Intervention: No RER (control group)
Number of subjects: 69
Study 21092279 — intervention group
Group type: EXPERIMENTAL
Intervention: FTIR spectroscopy applied to sputum
Number of subjects: 50
Study 21092279 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (normal sputum)
Number of subjects: 50
Study 21093024 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 317 (IL-4 receptor α antagonist)
Number of subjects: 292
Study 21093024 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual components of the ACQ
Number of subjects: 292
Study 21093024 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite ACQ score measurement
Number of subjects: 292
Study 21093024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 21093448 — intervention group
Group type: EXPERIMENTAL
Intervention: ANRS HIV-LIPO-5 Vaccine (dendritic cell vaccine loaded with HIV-1-antigen lipopeptides)
Number of subjects: 0
Study 21093448 — intervention group
Group type: EXPERIMENTAL
Intervention: ANRS HIV-LIPO-5 Vaccine
Number of subjects: 0
Study 21093611 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardiac monitor
Number of subjects: 271
Study 21093871 — intervention group
Group type: EXPERIMENTAL
Intervention: SAI QRST (sum magnitude of the absolute QRST integral)
Number of subjects: 508
Study 21093871 — intervention group
Group type: EXPERIMENTAL
Intervention: SAI QRST not exceeding 145 mV ms
Number of subjects: 508
Study 21093871 — intervention group
Group type: EXPERIMENTAL
Intervention: High SAI QRST
Number of subjects: 508